GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
CA2115742A1
(en)
|
1991-08-20 |
1993-03-04 |
Ronald G. Crystal |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
DE69229477T2
(de)
|
1991-09-23 |
1999-12-09 |
Cambridge Antibody Tech |
Methoden zur Herstellung humanisierter Antikörper
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
EP1136556B1
(en)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Method of producing multivalent antigen-binding proteins
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
CA2592997A1
(en)
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Pseudo-adenovirus vectors
|
CA2115811A1
(en)
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
ES2249761T3
(es)
|
1993-06-24 |
2006-04-01 |
Advec Inc. |
Vectores de adenovirus para terapia genica.
|
ES2171465T3
(es)
|
1993-09-01 |
2002-09-16 |
Sanquin Bloedvoorziening |
Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
|
EP2113569A1
(en)
|
1993-10-25 |
2009-11-04 |
CANJI, Inc. |
Recombinant adenoviral vector and methods of use
|
PT889120E
(pt)
|
1994-12-09 |
2002-09-30 |
Microscience Ltd |
Genes de virulencia no grupo vgc2 de salmonella
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
JP2003529536A
(ja)
|
1999-02-09 |
2003-10-07 |
3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド |
C1s介在疾患および状態の処置法、およびそれのための化合物および組成物
|
WO2000064327A2
(en)
|
1999-04-26 |
2000-11-02 |
Duke University |
Inhibition of complement action
|
WO2001013945A1
(en)
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
DK1252184T3
(da)
|
2000-01-31 |
2008-02-04 |
Pharming Intellectual Pty Bv |
Human C1-inhibitor produceret i mælk af transgene dyr
|
ATE435873T1
(de)
|
2000-03-23 |
2009-07-15 |
Genentech Inc |
Anti-c2/c2a inhibitoren zur komplement aktivierung
|
AU2001282857A1
(en)
|
2000-06-21 |
2002-01-02 |
Zymogenetics Inc. |
Peptide and polypeptide inhibitors of complement c1s
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
CA2454562A1
(en)
|
2001-07-26 |
2003-02-06 |
Alexion Pharmaceuticals, Inc. |
Method of improving cognitive function
|
US20080206242A1
(en)
*
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
ES2614274T3
(es)
|
2002-09-06 |
2017-05-30 |
Alexion Pharmaceuticals, Inc. |
Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
ES2387275T3
(es)
|
2003-05-15 |
2012-09-19 |
Genentech, Inc. |
Métodos y composiciones para la prevención y el tratamiento de la sepsis
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
AU2004297616B2
(en)
*
|
2003-12-04 |
2008-12-18 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
LT1753456T
(lt)
|
2004-06-10 |
2016-11-10 |
Omeros Corporation |
Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu, gydymo būdai
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US20060018896A1
(en)
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
WO2006063150A2
(en)
|
2004-12-08 |
2006-06-15 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
CA2601523A1
(en)
|
2005-03-16 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
|
US7897561B2
(en)
|
2005-06-06 |
2011-03-01 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
KR101691692B1
(ko)
|
2005-10-21 |
2016-12-30 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
보체 활성화를 억제하는 변형된 프로테아제
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
US8148330B2
(en)
|
2005-12-09 |
2012-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
US8071532B2
(en)
|
2005-12-21 |
2011-12-06 |
Pharming Intellectual Property B.V. |
Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
|
FR2897868B1
(fr)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
CN104623692A
(zh)
|
2006-03-08 |
2015-05-20 |
阿切埃米克斯股份有限公司 |
治疗视觉失调中使用的补体结合适体和抗-c5药物
|
CA2662480C
(en)
|
2006-09-05 |
2016-11-08 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
US8703136B2
(en)
|
2006-10-10 |
2014-04-22 |
Regenesance B.V. |
Complement inhibition for improved nerve regeneration
|
JP5586961B2
(ja)
|
2006-12-19 |
2014-09-10 |
バーシテック、リミテッド |
合成イオンチャネル
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
MY150531A
(en)
|
2007-07-16 |
2014-01-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
ES2622107T3
(es)
|
2007-08-03 |
2017-07-05 |
Genentech, Inc. |
Antagonistas anti-FGF19 humanizados y métodos de uso de los mismos
|
EP2278987A4
(en)
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
WO2009132058A2
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
WO2009151634A1
(en)
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
PL2894165T3
(pl)
|
2008-11-10 |
2023-04-17 |
Alexion Pharmaceuticals, Inc. |
Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
|
BRPI0923199B8
(pt)
|
2008-12-01 |
2021-07-27 |
Univ Leland Stanford Junior |
método para determinar a presença de anticorpos de fixação de complemento
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
JP2012531418A
(ja)
|
2009-06-23 |
2012-12-10 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体タンパク質に結合する二重特異性抗体
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
RU2600876C2
(ru)
|
2009-10-16 |
2016-10-27 |
Омерос Корпорейшен |
Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента
|
WO2011102342A1
(ja)
*
|
2010-02-16 |
2011-08-25 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
SG183541A1
(en)
|
2010-03-01 |
2012-10-30 |
Alexion Pharma Inc |
Methods and compositions for treating degos' disease
|
NZ603226A
(en)
|
2010-04-30 |
2015-02-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
AU2011256290B2
(en)
|
2010-05-17 |
2014-06-12 |
The Board Of Regents Of The University Of Texas System |
Rapid isolation of monoclonal antibodies from animals
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
CN103249432A
(zh)
|
2010-06-22 |
2013-08-14 |
科罗拉多大学董事会,法人团体 |
补体成分3的C3d片段的抗体
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
LT2648752T
(lt)
|
2010-12-06 |
2017-04-10 |
Seattle Genetics, Inc. |
Humanizuoti antikūnai prieš liv-1 ir jų panaudojimas vėžio gydymui
|
NZ731596A
(en)
|
2011-04-08 |
2022-07-01 |
Omeros Corp |
Methods for treating conditions associated with masp-2 dependent complement activation
|
WO2012151481A1
(en)
|
2011-05-04 |
2012-11-08 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
KR102022231B1
(ko)
|
2011-12-22 |
2019-09-19 |
체에스엘 베링 게엠베하 |
중추 신경계의 2차 부종을 치료하기 위한 c1-억제제의 용도
|
JP6081699B2
(ja)
*
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Il−28bの分析方法
|
AU2013334229B2
(en)
|
2012-10-25 |
2018-02-15 |
Bioverativ Usa Inc. |
Anti-complement C1s antibodies and uses thereof
|
EP3906944A1
(en)
|
2012-11-02 |
2021-11-10 |
Bioverativ USA Inc. |
Anti-complement c1s antibodies and uses thereof
|
US10280215B2
(en)
|
2013-01-31 |
2019-05-07 |
Seoul National University R&Db Foundation |
Anti-C5 antibodies and methods of treating complement-related diseases
|
EA037325B1
(ru)
|
2013-07-09 |
2021-03-12 |
Аннексон, Инк. |
Антитела против фактора комплемента c1q и их применения
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
SG10201909180SA
(en)
|
2015-04-06 |
2019-11-28 |
Bioverativ Usa Inc |
Humanized anti-c1s antibodies and methods of use thereof
|
EP3313417A4
(en)
|
2015-06-26 |
2019-06-12 |
Bioverativ USA Inc. |
METHODS OF TREATING AUTOIMMUNE AND ALLO-IMMUNE DISORDERS
|
BR112019007309A2
(pt)
|
2016-10-12 |
2019-07-02 |
Bioverativ Usa Inc |
anticorpos anti-c1s e métodos de uso dos mesmos
|
KR20190128676A
(ko)
|
2017-03-14 |
2019-11-18 |
바이오버라티브 유에스에이 인코포레이티드 |
보체-매개된 질환 및 장애의 치료 방법
|